WO2007075572A3 - Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90 - Google Patents

Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90 Download PDF

Info

Publication number
WO2007075572A3
WO2007075572A3 PCT/US2006/048250 US2006048250W WO2007075572A3 WO 2007075572 A3 WO2007075572 A3 WO 2007075572A3 US 2006048250 W US2006048250 W US 2006048250W WO 2007075572 A3 WO2007075572 A3 WO 2007075572A3
Authority
WO
WIPO (PCT)
Prior art keywords
heat shock
shock protein
orally active
based inhibitors
hsp90
Prior art date
Application number
PCT/US2006/048250
Other languages
English (en)
Other versions
WO2007075572A2 (fr
Inventor
Srinivas R Kasibhatla
Lin Zhang
Marcus F Boehm
Junhua Fan
Kevin D Hong
Marco Biamonte
Jiandong Shi
Original Assignee
Conforma Therapeutics Corp
Srinivas R Kasibhatla
Lin Zhang
Marcus F Boehm
Junhua Fan
Kevin D Hong
Marco Biamonte
Jiandong Shi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp, Srinivas R Kasibhatla, Lin Zhang, Marcus F Boehm, Junhua Fan, Kevin D Hong, Marco Biamonte, Jiandong Shi filed Critical Conforma Therapeutics Corp
Priority to CA002634723A priority Critical patent/CA2634723A1/fr
Priority to EP06845721A priority patent/EP1962863A4/fr
Priority to AU2006331917A priority patent/AU2006331917A1/en
Priority to JP2008547398A priority patent/JP2009521446A/ja
Publication of WO2007075572A2 publication Critical patent/WO2007075572A2/fr
Publication of WO2007075572A3 publication Critical patent/WO2007075572A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de purine innovants, leurs tautomères et leurs sels pharmaceutiquement acceptables ainsi que les compositions pharmaceutiquement et les complexes qui les comprennent, par exemple les complexes de HSP90, et leurs procédés d'utilisation. Les procédés d'utilisation des composés de purine innovants de l'invention, de leurs tautomères et de leurs sels pharmaceutiquement acceptables incluent leur utilisation pour inhiber les protéines de choc thermique 90 (HSP90) afin de traiter ou de prévenir les maladies liées aux HSP90, par exemple les troubles prolifératifs tels que le cancer du sein.
PCT/US2006/048250 2005-12-22 2006-12-18 Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90 WO2007075572A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002634723A CA2634723A1 (fr) 2005-12-22 2006-12-18 Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
EP06845721A EP1962863A4 (fr) 2005-12-22 2006-12-18 Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
AU2006331917A AU2006331917A1 (en) 2005-12-22 2006-12-18 Orally active purine-based inhibitors of heat shock protein 90
JP2008547398A JP2009521446A (ja) 2005-12-22 2006-12-18 熱ショックタンパク質９０の経口活性なプリンベースの阻害剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75363605P 2005-12-22 2005-12-22
US75344805P 2005-12-22 2005-12-22
US75369805P 2005-12-22 2005-12-22
US60/753,448 2005-12-22
US60/753,636 2005-12-22
US60/753,698 2005-12-22

Publications (2)

Publication Number Publication Date
WO2007075572A2 WO2007075572A2 (fr) 2007-07-05
WO2007075572A3 true WO2007075572A3 (fr) 2009-05-07

Family

ID=38218505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048250 WO2007075572A2 (fr) 2005-12-22 2006-12-18 Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90

Country Status (5)

Country Link
EP (1) EP1962863A4 (fr)
JP (1) JP2009521446A (fr)
AU (1) AU2006331917A1 (fr)
CA (1) CA2634723A1 (fr)
WO (1) WO2007075572A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652263A1 (fr) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Composes therapeutiques et leur utilisation contre le cancer
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
WO2009065035A1 (fr) * 2007-11-14 2009-05-22 Myriad Genetics, Inc. Composés thérapeutiques et leur utilisation dans le traitement de maladies et de troubles
EP2387316A4 (fr) 2009-01-16 2012-06-13 Curis Inc Aminopyridines fusionnées pour le traitement de tumeurs cérébrales
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
CA2885259A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associee a la tropomyosine pyrrolo[3,2-c]pyridine
MX370664B (es) 2013-08-16 2019-12-19 Memorial Sloan Kettering Cancer Center Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CN109721499A (zh) * 2018-12-19 2019-05-07 南京杰科丰环保技术装备研究院有限公司 一种硝基甲苯加氢制备甲基苯胺的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971972A (en) * 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US20040092520A1 (en) * 2002-10-28 2004-05-13 Pfizer Inc. Purine compounds and uses thereof
US20050113340A1 (en) * 2003-09-18 2005-05-26 Conforma Therapeutics Corporation 2-Aminopurine analogs having HSP90-inhibiting activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426952C (fr) * 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Compositions renfermant des petites molecules destinees a se lier a hsp90
EP2336133A1 (fr) * 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Analogues de purine présentant une activité inhibitrice de HSP90
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971972A (en) * 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US20040092520A1 (en) * 2002-10-28 2004-05-13 Pfizer Inc. Purine compounds and uses thereof
US20050113340A1 (en) * 2003-09-18 2005-05-26 Conforma Therapeutics Corporation 2-Aminopurine analogs having HSP90-inhibiting activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1962863A4 *

Also Published As

Publication number Publication date
AU2006331917A1 (en) 2007-07-05
JP2009521446A (ja) 2009-06-04
WO2007075572A2 (fr) 2007-07-05
CA2634723A1 (fr) 2007-07-05
EP1962863A4 (fr) 2010-11-24
EP1962863A2 (fr) 2008-09-03

Similar Documents

Publication Publication Date Title
WO2007075572A3 (fr) Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
WO2007056163A3 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
WO2004058769A3 (fr) Compositions utiles en tant qu'inhibiteurs des proteine kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2005056547A3 (fr) Quinoxalines utiles comme inhibiteurs des proteines kinases
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
WO2007041130A3 (fr) Deazapurines convenant comme inhibiteurs des janus kinases
WO2005103050A3 (fr) Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
WO2006023704A3 (fr) Analogues de lonidamine et leur utilisation dans la contraception masculine et dans le traitement du cancer
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
WO2008115973A3 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs de kinase
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007022384A3 (fr) Inhibiteurs de pyrazine kinases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680052735.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006845721

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2634723

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547398

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5542/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006331917

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006331917

Country of ref document: AU

Date of ref document: 20061218

Kind code of ref document: A